MNK

Mallinckrodt (MNK)

Mallinckrodt Plc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:MNK

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/02/28	03:00	PR Newswire (US)	Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results	NYSE:MNK	Mallinckrodt Plc
2024/12/02	20:45	PR Newswire (US)	Mallinckrodt Completes Divestiture of Therakos® Business	NYSE:MNK	Mallinckrodt Plc
2024/11/19	01:00	PR Newswire (US)	Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting	NYSE:MNK	Mallinckrodt Plc
2024/11/14	23:05	PR Newswire (US)	Mallinckrodt to Present at Jefferies London Healthcare Conference	NYSE:MNK	Mallinckrodt Plc
2024/11/05	20:45	PR Newswire (US)	Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance	NYSE:MNK	Mallinckrodt Plc
2024/10/30	19:50	PR Newswire (US)	Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting	NYSE:MNK	Mallinckrodt Plc
2024/10/29	21:30	PR Newswire (US)	Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeting	NYSE:MNK	Mallinckrodt Plc
2024/10/27	02:00	PR Newswire (US)	Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024	NYSE:MNK	Mallinckrodt Plc
2024/10/24	19:45	PR Newswire (US)	Mallinckrodt to Report Earnings Results for Third Quarter 2024	NYSE:MNK	Mallinckrodt Plc
2024/10/10	19:52	PR Newswire (US)	Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals	NYSE:MNK	Mallinckrodt Plc
2024/09/17	19:50	PR Newswire (US)	Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector	NYSE:MNK	Mallinckrodt Plc
2024/09/03	16:45	PR Newswire (US)	THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)	NYSE:MNK	Mallinckrodt Plc
2024/08/06	19:45	PR Newswire (US)	Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance	NYSE:MNK	Mallinckrodt Plc
2024/08/06	19:35	PR Newswire (US)	Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.	NYSE:MNK	Mallinckrodt Plc
2024/08/05	20:00	PR Newswire (US)	Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million	NYSE:MNK	Mallinckrodt Plc
2024/08/05	20:00	PR Newswire (US)	Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million	NYSE:MNK	Mallinckrodt Plc
2024/08/01	21:59	PR Newswire (US)	Mallinckrodt to Report Earnings Results for Second Quarter 2024	NYSE:MNK	Mallinckrodt Plc
2024/06/05	19:45	PR Newswire (US)	Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress	NYSE:MNK	Mallinckrodt Plc
2024/05/18	20:00	PR Newswire (US)	Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)	NYSE:MNK	Mallinckrodt Plc
2024/05/09	19:45	PR Newswire (US)	Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance	NYSE:MNK	Mallinckrodt Plc
2024/03/27	05:01	PR Newswire (US)	Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance	NYSE:MNK	Mallinckrodt Plc
2024/03/11	19:52	PR Newswire (US)	Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients	NYSE:MNK	Mallinckrodt Plc
2024/03/04	20:45	PR Newswire (US)	Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands	NYSE:MNK	Mallinckrodt Plc
2024/03/01	22:50	PR Newswire (US)	Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector	NYSE:MNK	Mallinckrodt Plc
2024/02/02	22:45	PR Newswire (US)	Mallinckrodt Announces Board of Directors and Leadership Updates	NYSE:MNK	Mallinckrodt Plc
2024/01/22	20:52	PR Newswire (US)	Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress	NYSE:MNK	Mallinckrodt Plc
2023/11/01	19:45	PR Newswire (US)	Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting	NYSE:MNK	Mallinckrodt Plc
2023/10/26	19:53	PR Newswire (US)	Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023	NYSE:MNK	Mallinckrodt Plc
2023/08/31	00:54	PR Newswire (US)	Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations	NYSE:MNK	Mallinckrodt Plc
2023/06/30	07:53	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:MNK	Mallinckrodt Plc